Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Glaxosmithkline Plc (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 99,181,960
  • Shares Outstanding, K 2,459,260
  • Annual Sales, $ 37,798 M
  • Annual Income, $ 1,236 M
  • 36-Month Beta 1.03
  • Price/Sales 2.62
  • Price/Cash Flow 10.09
  • Price/Book 17.53

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.07 +3.86%
on 08/29/17
40.74 -0.39%
on 09/22/17
+1.45 (+3.71%)
since 08/22/17
3-Month
38.60 +5.13%
on 08/21/17
44.44 -8.69%
on 06/26/17
-3.58 (-8.11%)
since 06/22/17
52-Week
37.20 +9.09%
on 12/08/16
44.53 -8.87%
on 05/31/17
-3.00 (-6.88%)
since 09/22/16

Most Recent Stories

More News
Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update

Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.

JNJ : 131.39 (-0.27%)
SUPN : 39.00 (-1.02%)
TEVA : 17.19 (+0.23%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
GSK : 40.58 (+0.62%)
BMY : 63.36 (+0.05%)
Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III

GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.

INVA : 13.78 (+2.15%)
ACAD : 37.59 (-0.11%)
GSK : 40.58 (+0.62%)
ADRO : 10.80 (-1.82%)
How GlaxoSmithKline (GSK) Stock Stands Out in a Strong Industry

GlaxoSmithKline (GSK) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

GSK : 40.58 (+0.62%)
Theravance Biopharma Highlights Positive Headline Results from IMPACT Study of Trelegy Ellipta Announced by GlaxoSmithKline and Innoviva

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today highlighted that GlaxoSmithKline plc (GSK) and Innoviva, Inc. (Innoviva) have reported positive headline results from the landmark...

TBPH : 33.49 (-0.03%)
GSK : 40.58 (+0.62%)
Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?

GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

GSK : 40.58 (+0.62%)
Sir Andrew Witty, Former CEO of GSK, Joins Synthego Advisory Board

Synthego strengthens position with appointment while accelerating worldwide commercial growth

GSK : 40.58 (+0.62%)
Sir Andrew Witty, Former CEO of GSK, Joins Synthego Advisory Board

Synthego strengthens position with appointment while accelerating worldwide commercial growth

GSK : 40.58 (+0.62%)
Sir Andrew Witty, Former CEO of GSK, Joins Synthego Advisory Board

Synthego strengthens position with appointment while accelerating worldwide commercial growth

GSK : 40.58 (+0.62%)
GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta, the first and...

INVA : 13.78 (+2.15%)
GSK : 40.58 (+0.62%)
FDA OKs Glaxo's inhaler, first one to combine 3 medicines

TRENTON, N.J. (AP) — The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis.

INVA : 13.78 (+2.15%)
GSK.LS : 1,474.000 (+0.41%)
GSK : 40.58 (+0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Support & Resistance

2nd Resistance Point 40.93
1st Resistance Point 40.75
Last Price 40.58
1st Support Level 40.39
2nd Support Level 40.21

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.